摘要
套细胞淋巴瘤(MCL)是一种侵袭性B细胞淋巴瘤,占非霍奇金淋巴瘤(NHL)的6%~8%.目前国际对于MCL在生物学行为、诊断标准、治疗原则等方面已有较多研究和报道.但由于其侵袭性较高,在预后判断、治疗方面仍然有许多问题有待解决.文章对MCL的疾病概况进行介绍,同时对于临床上尚未解决问题的最新进展进行阐述.
Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma, accounting for around 6%-8% of non-Hodgkin's lymphoma (NHL). Up to now, there are a lot of studies and reports on the biological behavior, diagnostic criteria and treatments of MCL worldwide. However, due to its high invasiveness, there are still many problems to be solved in terms of prognosis and treatment. This article introduces MCL and its progress in the unsolved clinical problems.
作者
王彩琴
高天晓
孙小晴
李志铭
Wang Caiqin;Gao Tianxiao;Sun Xiaoqing;Li Zhiming(Sun Yat-Sen University Cancer Center,Guangzhou 510060,China)
出处
《白血病．淋巴瘤》
CAS
2019年第11期701-704,共4页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
膜细胞
流行病学
治疗
进展
Lymphoma,mantle-cell
Epidemiology
Treatment
Progress
